CINACALCET HYDROCHLORIDE Drug Patent Profile
✉ Email this page to a colleague
When do Cinacalcet Hydrochloride patents expire, and when can generic versions of Cinacalcet Hydrochloride launch?
Cinacalcet Hydrochloride is a drug marketed by Accord Hlthcare, Alkem Labs Ltd, Aurobindo Pharma Ltd, Chartwell Rx, Cipla, Dr Reddys, Hetero Labs Ltd V, Lupin Ltd, Mylan, Slate Run Pharma, Stevens J, Strides Pharma, Sun Pharm, and Watson Labs Teva. and is included in fourteen NDAs.
The generic ingredient in CINACALCET HYDROCHLORIDE is cinacalcet hydrochloride. There are twenty-four drug master file entries for this compound. Twenty suppliers are listed for this compound. Additional details are available on the cinacalcet hydrochloride profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Cinacalcet Hydrochloride
A generic version of CINACALCET HYDROCHLORIDE was approved as cinacalcet hydrochloride by AUROBINDO PHARMA LTD on March 8th, 2018.
Summary for CINACALCET HYDROCHLORIDE
Recent Clinical Trials for CINACALCET HYDROCHLORIDE
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
Shanghai Hengrui Pharmaceutical Co., Ltd. | Phase 2 |
VA Office of Research and Development | Phase 4 |
University of California, San Francisco | Phase 4 |
Pharmacology for CINACALCET HYDROCHLORIDE
Drug Class | Calcium-sensing Receptor Agonist |
Mechanism of Action | Increased Calcium-sensing Receptor Sensitivity |
Medical Subject Heading (MeSH) Categories for CINACALCET HYDROCHLORIDE
Anatomical Therapeutic Chemical (ATC) Classes for CINACALCET HYDROCHLORIDE
Paragraph IV (Patent) Challenges for CINACALCET HYDROCHLORIDE
Tradename | Dosage | Ingredient | Strength | NDA | ANDAs Submitted | Submissiondate |
---|---|---|---|---|---|---|
SENSIPAR | Tablets | cinacalcet hydrochloride | 30 mg, 60 mg and 90 mg | 021688 | 1 | 2008-03-10 |